Disappointing sales for its two vaccine flagships, Shingrix and Arexvy, have hit GSK in the third quarter, but were partly offset by strong growth in its speciality medicines.
Speciality Medicines Rescue GSK’s Q3 As Vaccines Sales Slump
Sales of Arexvy fell back in the third quarter but GSK’s leadership believes the vaccine and several pipeline drugs can help the company achieve higher growth.
